New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export TVRD’s income statement to Excel — free account
Tvardi Therapeutics, Inc.
TVRDTvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.
- Revenue
- +20.3%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
0.99
0.04
+4.21%
After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.
Follow TVRD
Alert me
Tvardi Therapeutics, Inc. (TVRD) news
Stories the last two months, newest first
More headlines
- Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference GlobeNewswire
- New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC) GlobeNewswire
- Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
- Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
- Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
- TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
- Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
- Tvardi Therapeutics to Participate in Upcoming Investor Events GlobeNewswire
- Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update GlobeNewswire
- Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium GlobeNewswire
- Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update GlobeNewswire
- Tvardi Therapeutics to Participate in Upcoming Investor Conferences
- We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate Simply Wall St.
- Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswireInsider MonkeySimply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.
- Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights GlobeNewswire
- Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Zacks
- Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference Business Wire
- Tvardi: Q3 Earnings Snapshot Associated Press Finance
- Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update Business Wire
- Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London Business Wire
- Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock Now Zacks
- Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround ZacksMT NewswiresZacksSimply Wall St.ZacksZacksZacksZacks
- TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals Zacks
- Why Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial Results Simply Wall St.
- Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis Business WireClinical Trials ArenaZacksPharmaceutical TechnologySimply Wall St.Clinical Trials ArenaClinical Trials ArenaSimply Wall St.
- Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26% Simply Wall St.
- Tvardi Therapeutics (NASDAQ:TVRD) Is In A Good Position To Deliver On Growth Plans